India's National Pharmaceutical Pricing Authority (NPPA) has set a 30% cap on trade margins for 137 anti-cancer drugs, including Atezolizumab and Bevacizumab. This regulation, effective from November 9, requires manufacturers to adjust prices if they exceed the newly calculated maximum retail price. State drug controllers and hospitals will oversee compliance, ensuring that prices align with the new cap. This move aims to make cancer treatments more affordable and accessible. For detailed information, refer to the official publication.
Read the original article